Moderna's Stock Down 10% After FDA Declines to Review New Influenza Vaccine Application

Moderna's stock dropped 10% to $37.93 after the FDA declined to review its new influenza vaccine application. The company faces financial challenges with negative margins and declining revenue growth. Despite this, Moderna maintains a strong Altman Z-Score, indicating financial resilience. The stock's beta of 1.06 suggests moderate volatility relative to the market. Investors should remain vigilant of sector-specific risks and monitor upcoming developments in Moderna's pipeline.